Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Buildings (2016 - 2023)

China Pharma Holdings filings provide 13 years of Buildings readings, the most recent being $9.1 million for Q2 2023.

  • On a quarterly basis, Buildings fell 7.12% to $9.1 million in Q2 2023 year-over-year; TTM through Jun 2023 was $9.1 million, a 7.12% decrease, with the full-year FY2022 number at $9.4 million, down 8.46% from a year prior.
  • Buildings hit $9.1 million in Q2 2023 for China Pharma Holdings, down from $9.5 million in the prior quarter.
  • In the past five years, Buildings ranged from a high of $10.3 million in Q1 2022 to a low of $9.1 million in Q2 2023.
  • Median Buildings over the past 5 years was $9.6 million (2020), compared with a mean of $9.7 million.
  • Biggest five-year swings in Buildings: rose 9.59% in 2021 and later decreased 8.65% in 2022.
  • China Pharma Holdings' Buildings stood at $9.4 million in 2019, then increased by 6.92% to $10.0 million in 2020, then rose by 2.34% to $10.3 million in 2021, then fell by 8.46% to $9.4 million in 2022, then decreased by 3.61% to $9.1 million in 2023.
  • The last three reported values for Buildings were $9.1 million (Q2 2023), $9.5 million (Q1 2023), and $9.4 million (Q4 2022) per Business Quant data.